Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.